Share

July 17, 2018; 91 (3) Views & Reviews

Critical appraisal of the recent US FDA approval for earlier DBS intervention

Laura Y. Cabrera, John Goudreau, Christos Sidiropoulos
First published June 13, 2018, DOI: https://doi.org/10.1212/WNL.0000000000005829
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
555

Share

Article Information

vol. 91 no. 3 133-136
DOI: 
https://doi.org/10.1212/WNL.0000000000005829
PubMed: 
29898975
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received December 12, 2017
  • Accepted in final form March 29, 2018
  • First Published June 13, 2018.

Article Versions

Copyright & Usage: 
© 2018 American Academy of Neurology

Author Disclosures

    1. Laura Y. Cabrera, PhD,
    2. John Goudreau, PhD, DO and
    3. Christos Sidiropoulos, MD
  1. Laura Y. Cabrera, PhD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. ERA-NET Neuron Team Grant: Ethical, Legal and Social (ELS) Issues #ERN- 144241, project leader, 2016-2019.

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. John Goudreau, PhD, DO and
    3. Scientific Advisory Boards:

    1. Teva

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Teva Acadia Adama

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. Teva Acadia Adamas

    Other Activities:

    1. NONE

    Clinical procedures or imaging studies:

    1. 15% effort for deep brain stimulation-related services

    Research Support, Commercial Entities:

    1. Biotie Pharmaceuticals Intec Pharmacueticals Sunovion Pharmaceuticals Pharma 2B

    Research Support, Government Entities:

    1. NINDS

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Michael J Fox Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Christos Sidiropoulos, MD
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Movement Disorders Society, Travel Grant

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Center of Ethics and Humanities in the Life Sciences (L.Y.C.) and Department of Neurology & Ophthalmology (J.G., C.S.), Michigan State University, East Lansing, MI.
  1. Correspondence
    Dr. Cabrera laura.cabrera{at}hc.msu.edu
View Full Text

Article usage

Article usage: June 2018 to April 2023

AbstractFullPdfSource
Jun 2018663043Highwire
Jul 20184047239Highwire
Aug 201810699Highwire
Sep 2018114315Highwire
Oct 2018106918Highwire
Nov 20181561139Highwire
Dec 2018149831Highwire
Jan 201998125Highwire
Feb 201992230Highwire
Mar 2019103142Highwire
Apr 201992447Highwire
May 201963519Highwire
Jun 201961230Highwire
Jul 201975229Highwire
Aug 20194476Highwire
Sep 20192937Highwire
Oct 201942210Highwire
Nov 20196704Highwire
Dec 20194905Highwire
Jan 20203326Highwire
Feb 20202611Highwire
Mar 20201926Highwire
Apr 20202113Highwire
May 20202211Highwire
Jun 20203600Highwire
Jul 20203701Highwire
Aug 20202900Highwire
Sep 20202111Highwire
Oct 20202232Highwire
Nov 20203710Highwire
Dec 202013900Highwire
Jan 20216951Highwire
Feb 20216801Highwire
Mar 20217232Highwire
Apr 20214812Highwire
May 20216001Highwire
Jun 20214800Highwire
Jul 202117522Highwire
Aug 202116100Highwire
Sep 20215402Highwire
Oct 20215634Highwire
Nov 20215400Highwire
Dec 20215410Highwire
Jan 20225132Highwire
Feb 20224511Highwire
Mar 20227002Highwire
Apr 202279211Highwire
May 20225216Highwire
Jun 202280112Highwire
Jul 20225618Highwire
Aug 20225404Highwire
Sep 20224435Highwire
Oct 20224309Highwire
Nov 20226012Highwire
Dec 20223400Highwire
Jan 20234900Highwire
Feb 20231702Highwire
Mar 20233511Highwire
Apr 20232106Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Recommended articles